How to buy Bionomics Limited American Depository Shares stock

Bionomics Limited American Depository Shares is a biotechnology business based in the US. Bionomics Limited American Depository Shares shares (BNOX) are listed on the NASDAQ and all prices are listed in US Dollars.

Bionomics Limited American Depository Shares stock price (NASDAQ: BNOX)

Use our graph to track the performance of BNOX stocks over time.

Bionomics Limited American Depository Shares shares at a glance

• Key figures

Information last updated 2022-01-24.

Latest market close	$12.97
52-week range	$10.53 - $22.00
50-day moving average more info button	$12.44
200-day moving average more info button	$12.44
Wall St. target price	N/A
PE ratio more info button	N/A
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$-0.16

Buy Bionomics Limited American Depository Shares shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bionomics Limited American Depository Shares stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bionomics Limited American Depository Shares price performance over time

Historical closes compared with the close of $12.97 from 2022-01-25

1 week (2022-01-19)	3.84%
1 month (2021-12-23)	5.02%
3 months (2021-10-22)	N/A
6 months (2021-07-22)	N/A

1 year (2021-01-22)	N/A
2 years (2020-01-22)	N/A
3 years (2019-01-22)	N/A
5 years (2017-01-22)	N/A

Bionomics Limited American Depository Shares financials

Revenue TTM	$928,073
Gross profit TTM	$-4,834,230
Return on assets TTM	-14.48%
Return on equity TTM	-28.86%
Profit margin	0%
Book value	$0.94
Market capitalisation more info button	$96.6 million

TTM: trailing 12 months

Bionomics Limited American Depository Shares share dividends

We're not expecting Bionomics Limited American Depository Shares to pay a dividend over the next 12 months.

You may also wish to consider:

• Merck-and-CoInc (MRK.US) (3.45% forward annual dividend yield)
• Johnson-and-Johnson (JNJ.US) (2.57% forward annual dividend yield)
• UnitedHealth Group Incorporated (UNH.US) (1.26% forward annual dividend yield)

Bionomics Limited American Depository Shares share price volatility

Over the last 12 months, Bionomics Limited American Depository Shares's shares have ranged in value from as little as $10.53 up to $22. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bionomics Limited American Depository Shares's is 2.6209. This would suggest that Bionomics Limited American Depository Shares's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put Bionomics Limited American Depository Shares's beta into context you can compare it against those of similar companies.

• Merck-and-CoInc (MRK.US): 0.4952
• Johnson-and-Johnson (JNJ.US): 0.7364
• UnitedHealth Group Incorporated (UNH.US): 0.8652

Bionomics Limited American Depository Shares overview

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co. , Inc. The company was incorporated in 1996 and is based in Eastwood, Australia. .

Frequently asked questions

What percentage of Bionomics Limited American Depository Shares is owned by institutions?
Currently 9.918% of Bionomics Limited American Depository Shares shares are held by institutions. When does the fiscal year end for Bionomics Limited American Depository Shares?
Bionomics Limited American Depository Shares's fiscal year ends in June.